Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in 20 countries. Backed by funds advised by Permira, Neuraxpharm has a unique understanding of the CNS market built over 35 years.
With more than 900 professionals, Neuraxpharm has a unique understanding of the CNS market built over 35 years. It has a direct presence in 19 countries and plans further geographic expansion as part of its strategy to strengthen its position as a European leader in CNS treatments.
With its focus on CNS, Neuraxpharm develops and commercializes established brands, value added medicines, generics, Consumer Healthcare products, medical cannabis and beyond-the-pill solutions and is continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.
With more than 130 molecules, Neuraxpharm has one of the largest drug portfolios of CNS treatment options that has been strategically developed to meet the needs of all CNS patients.
Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products (FDFs) and active pharmaceutical ingredients (APIs) in its own manufacturing sites in Spain, Lesvi and Inke.